What question did this study set out to answer?

This research aims to evaluate the cost-effectiveness and public health impact of the LP.8.1-adapted Pfizer-BioNTech COVID-19 vaccine for high-risk adults.

March 30, 2026Open Access

Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States

Key Points

This research aims to evaluate the cost-effectiveness and public health impact of the LP.8.1-adapted Pfizer-BioNTech COVID-19 vaccine for high-risk adults.
Projected analysis of vaccination costs and health outcomes
Societal perspective assessment of economic impact
Comparison of health burden before and after vaccination
Vaccination is expected to be cost-saving from a societal perspective
Potential reduction in public health burden related to COVID-19
Improved health outcomes for high-risk adults through vaccination

Abstract

Vaccinating adults at high risk of severe COVID-19 with the LP.8.1-adapted Pfizer BioNTech COVID-19 Vaccine is projected to be a cost-saving measure from the societal perspective that could reduce the public health and economic burden of COVID-19.

Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States

Key Points

Abstract

Cite This Study